Viaskin™ Peanut’s Long-Term Phase III Updates and What the FDA Has to Say About Them

BioSpace spoke with Mohideen and Todd Green, MD, pediatric allergist and VP of Clinical Development and Medical Affairs at DBV, about their recently published Phase III open-label extension trial data, touching on the FDA’s recent decision to deny approval of Viaskin™ Peanut in its current form and what the next steps are. Rose Joachim, Ph.D., a Senior Healthcare Analyst at GlobalData, also provided insights into how Viaskin™ Peanut fits into the landscape of peanut immunotherapy.